XML 81 R49.htm IDEA: XBRL DOCUMENT
v3.19.1

Revenues Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2019 | Mar. 31, 2018
Disaggregation of Revenue [Line Items] |  |
Total revenues from anti-CD20 therapeutic programs | $ 3,489.8 | $ 3,131.1
Genentech |  |
Disaggregation of Revenue [Line Items] |  |
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA | 390.8 | 349.6
Other revenues from anti-CD20 therapeutic programs | 126.6 | 93.6
Revenues from anti-CD20 therapeutic programs |  |
Disaggregation of Revenue [Line Items] |  |
Total revenues from anti-CD20 therapeutic programs | $ 517.4 | $ 443.2

X
- Definition Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus. + References No definition available. + Details
Name: | biib_OtherrevenuesfromantiCD20therapeuticprograms
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Share of co promotion profits. + References No definition available. + Details
Name: | biib_ShareOfCoPromotionProfits
Namespace Prefix: | biib_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=biib_RocheGroupGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |